Physician profile
Antoine G Tohmeh
NPI 1366549040
$4,264,198.75
in general payments reported to CMS, 2019-2025
15 companies · $1.1M in 2025
The $1.1M reported for 2025 was more than what 99% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $365K · 2021: $452K · 2022: $548K · 2023: $776K · 2024: $870K · 2025: $1.1M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.6M · Consulting Fee: $123K · Travel and Lodging: $18K · Food and Beverage: $3,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,615,541.61 |
| Consulting Fee | $122,645.08 |
| Travel and Lodging | $17,886.55 |
| Food and Beverage | $3,497.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $2,846,412.59 | 2019-2025 | Safeop, Identiti, Other - Miscellaneous |
| Nuvasive, INC. | $1,037,873.65 | 2019-2023 | Cohere, Coroent, Maxcess |
| Globus Medical, INC. | $378,853.57 | 2024-2025 | Tlif, Cohere, Modulus |
| Boston Scientific Corporation | $324.07 | 2024-2025 | Intracept Rf Probe, General - Pain Management |
| Si-Bone, INC. | $217.38 | 2022-2024 | |
| Seaspine Orthopedics Corporation | $150.00 | 2019 | |
| Mml US, INC. | $111.90 | 2022 | |
| Nevro Corp. | $97.78 | 2024 | Senza |
| Medtronic, INC. | $45.08 | 2021 | |
| Collegium Pharmaceutical, INC. | $42.80 | 2024 | Belbuca |
| Pfizer INC. | $29.76 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.74 | 2025 | Relistor |
| Medtronic USA, INC. | $12.30 | 2019 | |
| Surgalign Spine Technologies, INC. | $12.13 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Tohmeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.